Search Results - "Maslyar, Daniel J."

A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer by Burke, James M, Lamm, Donald L, Meng, Maxwell V, Nemunaitis, John J, Stephenson, Joseph J, Arseneau, James C, Aimi, Junko, Lerner, Seth, Yeung, Alex W, Kazarian, Troy, Maslyar, Daniel J, McKiernan, James M

“…We assessed the safety, pharmacokinetics and anticancer activity of intravesical CG0070, a cancer selective, replication competent adenovirus, for the…”
Get more information

Small-Molecule Antagonists of Myc/Max Dimerization Inhibit Myc-Induced Transformation of Chicken Embryo Fibroblasts by Berg, Thorsten, Cohen, Steven B., Desharnais, Joel, Sonderegger, Corinna, Maslyar, Daniel J., Goldberg, Joel, Boger, Dale L., Vogt, Peter K.

“…Myc is a transcriptional regulator of the basic helix-loop-helix leucine zipper protein family. It has strong oncogenic potential, mutated or virally…”
Get full text

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss by de Bono, Johann S, De Giorgi, Ugo, Rodrigues, Daniel Nava, Massard, Christophe, Bracarda, Sergio, Font, Albert, Arranz Arija, Jose Angel, Shih, Kent C, Radavoi, George Daniel, Xu, Na, Chan, Wai Y, Ma, Han, Gendreau, Steven, Riisnaes, Ruth, Patel, Premal H, Maslyar, Daniel J, Jinga, Viorel

“…PI3K-Akt-mTOR and androgen receptor (AR) signaling are commonly aberrantly activated in metastatic castration-resistant prostate cancer (mCRPC), with PTEN loss…”
Get full text

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial by Kim, Sung-Bae, Dent, Rebecca, Im, Seock-Ah, Espié, Marc, Blau, Sibel, Tan, Antoinette R, Isakoff, Steven J, Oliveira, Mafalda, Saura, Cristina, Wongchenko, Matthew J, Kapp, Amy V, Chan, Wai Y, Singel, Stina M, Maslyar, Daniel J, Baselga, José, Kim, Sung-Bae, Lee, Keun Seok, Im, Seock-Ah, Espié, Marc, Wang, Hwei-Chung, Blau, Sibel, Dent, Rebecca, Tan, Antoinette, Sohn, Joo Hyuk, De Laurentiis, Michelino, Estevez, Laura Garcia, Huang, Chiun-Sheng, Romieu, Gilles, Velez, Michel, Villanueva, Rafael, Conte, Pier Franco, Dakhil, Shaker, Debled, Marc, Martin, Antonio Gonzalez, Hurvitz, Sara, Kim, Jee Hyun, Levy, Christelle, Oliveira, Mafalda, Rovira, Pedro Sanchez, Seo, Jae Hong, Valero, Vicente, Vidal, Gregory, Wong, Andrea, Allison, Mary Ann K, Figlin, Robert, Chan, David, Chen, Shin-Cheh, Chen, Yen-Hsun, Cobleigh, Melody, De Braud, Filippo, Dirix, Luc, Hansen, Vincent, Bessard, Anne Hardy, Iannotti, Nicholas, Isakoff, Steven, Lawler, William, Montaño, Alvaro, Salkini, Mohamad, Seigel, Leonard

“…The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast…”
Get full text

Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer by Danila, Daniel C, Szmulewitz, Russell Z, Vaishampayan, Ulka, Higano, Celestia S, Baron, Ari D, Gilbert, Houston N, Brunstein, Flavia, Milojic-Blair, Marija, Wang, Bei, Kabbarah, Omar, Mamounas, Michael, Fine, Bernard M, Maslyar, Daniel J, Ungewickell, Alexander, Scher, Howard I

“…Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) is highly expressed in prostate cancers. DSTP3086S is a humanized immunoglobulin G1 anti-STEAP1…”
Get full text

Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer by Weekes, Colin D, Lamberts, Laetitia E, Borad, Mitesh J, Voortman, Johannes, McWilliams, Robert R, Diamond, Jennifer R, de Vries, Elisabeth G E, Verheul, Henk M, Lieu, Christopher H, Kim, George P, Wang, Yulei, Scales, Suzie J, Samineni, Divya, Brunstein, Flavia, Choi, YounJeong, Maslyar, Daniel J, Colon-Otero, Gerardo

“…DMOT4039A, a humanized anti-mesothelin mAb conjugated to the antimitotic agent monomethyl auristatin E (MMAE), was given to patients with pancreatic and…”
Get full text

Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML) by Borrello, Ivan M., Levitsky, Hyam I., Stock, Wendy, Sher, Dorie, Qin, Lu, DeAngelo, Daniel J., Alyea, Edwin P., Stone, Richard M., Damon, Lloyd E., Linker, Charles A., Maslyar, Daniel J., Hege, Kristen M.

“…Preclinical models have demonstrated the efficacy of granulocyte-macrophage colony-stimulating factor-secreting cancer immunotherapies (GVAX platform)…”
Get full text

Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC) by Dent, Rebecca, Im, Seock-Ah, Espie, Marc, Blau, Sibel, Tan, Antoinette R., Isakoff, Steven J., Oliveira, Mafalda, Saura, Cristina, Wongchenko, Matthew, Kapp, Amy V., Chan, Wai Y., Singel, Stina M., Maslyar, Daniel J., Baselga, Jose, Kim, Sung-Bae

“…Abstract only…”
Get full text

Mechanisms of and potential treatment strategies for metastatic disease in non-small cell lung cancer by Maslyar, Daniel J, Jahan, Thierry M, Jablons, David M

“…Lung cancer consumes over one million lives in the world every year, with surgical resection playing a dominant role in the curative treatment of lung cancer…”
Get full text

LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC) by Dent, Rebecca Alexandra, Kim, Sung-Bae, Im, Seock-Ah, Espie, Marc, Blau, Sibel, Tan, Antoinette R., Isakoff, Steven, Oliveira, Mafalda, Saura, Cristina, Wongchenko, Matthew, Kapp, Amy V., Chan, Wai Y., Singel, Stina M., Maslyar, Daniel J., Baselga, Jose

“…Abstract only 1009 Background: The oral Akt inhibitor IPAT is being evaluated in cancers with a high prevalence of PI3K/Akt pathway activation, including TNBC…”
Get full text

Abstract CT041: Primary results from FAIRLANE (NCT02301988), a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (eTNBC) by Oliveira, Mafalda, Saura, Cristina, Calvo, Isabel, Andersen, Jay, Coelho, José Luis Passos, Gil, Miguel Gil, Bermejo, Begoña, Patt, Debra A., Ciruelos, Eva, Singel, Stina M., Maslyar, Daniel J., Wongchenko, Matthew, Chan, Wai Y., Kapp, Amy V., Peña, Lorena de la, Baselga, José, Isakoff, Steven J.

“…Abstract Purpose: This hypothesis-generating trial evaluated neoadjuvant IPAT + PAC for eTNBC. Methods: Patients (pts) with eTNBC, T ≥1.5 cm and N0-2 were…”
Get full text

NGS, RNA-Seq, TIL, and PTEN analyses in prostate cancer specimens from patients enrolled in the study of the Akt inhibitor ipatasertib (Ipat) combined with abiraterone acetate (AA) by Zhang, Liangxuan, Koeppen, Hartmut, Maslyar, Daniel J., Fillos, Dimitri, Xu, Na, Chan, Wai Y., Font Pous, Albert, Jinga, Viorel, Massard, Christophe, Bracarda, Sergio, Radavoi, George Daniel, De Giorgi, Ugo, Arranz Arija, Jose Angel, Riisnaes, Ruth, Nava Rodrigues, Daniel, De Bono, Johann S., Gendreau, Steven

“…Abstract only 310 Background: In Phase III studies, ipilimumab did not extend OS in unselected populations with metastatic castration-resistant prostate cancer…”
Get full text

FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (GDC-0068) in combination with paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer by Isakoff, Steven J., Saura, Cristina, Calvo, Isabel, Gil Gil, Miguel J., Patt, Debra A., Morales Murillo, Serafin, Andersen, Jay C., Ciruelos, EVA, Fisher, Julie Gottlieb, Passos-Coelho, Jose, de La Pena, Lorena, Kapp, Amy V., Gendreau, Steven, Chan, Wai Y., Singel, Stina Mui, Maslyar, Daniel J., Baselga, Jose, Oliveira, Mafalda

“…Abstract only…”
Get full text

Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study) by De Bono, Johann S., De Giorgi, Ugo, Massard, Christophe, Bracarda, Sergio, Kocak, Ivo, Font, Albert, Arranz Arija, Jose Angel, Shih, Kent C., Radavoi, George Daniel, Yu, Wei, Chan, Wai Y., Huang, Jian, Musib, Luna C., Gendreau, Steven, Meng, Raymond D., Patel, Premal H, Maslyar, Daniel J., Jinga, Viorel

“…Abstract only…”
Get full text

A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC) by Banerjee, Susana N., Oza, Amit M., Birrer, Michael J., Hamilton, Erika Paige, Hasan, Jurjees, Leary, Alexandra, Moore, Kathleen N., Mackowiak-Matejczyk, Beata, Pikiel, Joanna, Ray-Coquard, Isabelle, Trask, Peter, Lin, Kedan, Vaze, Anjali, Choi, YounJeong, Marsters, Jim, Maslyar, Daniel J., Lemahieu, Vanessa, Wang, Yulei, Humke, Eric William, Liu, Joyce F.

“…Abstract only…”
Get full text

A phase I study of DSTP3086S, an antibody-drug conjugate (ADC) targeting STEAP-1, in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) by Danila, Daniel Costin, Szmulewitz, Russell Zelig, Baron, Ari David, Higano, Celestia S., Scher, Howard I., Morris, Michael J., Gilbert, Houston, Brunstein, Flavia, Lemahieu, Vanessa, Kabbarah, Omar, Fine, Bernard M., Maslyar, Daniel J., Vaishampayan, Ulka N.

“…Abstract only…”
Get full text

A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC) by Burris, Howard A., Gordon, Michael S., Gerber, David E., Spigel, David R., Mendelson, David S., Schiller, Joan H., Wang, Yulei, Choi, Younjeong, Kahn, Robert S., Wood, Katie, Maslyar, Daniel J., Infante, Jeffrey R.

“…Abstract only…”
Get full text

STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC) by Danila, Daniel Costin, Fleisher, Martin, Carrasquillo, Jorge A., Gilbert, Houston, Morris, Michael J., Bellomo, Lawrence P, Hendrikx, Petrus J, Szafer-Glusman, Edith, Herkal, Amrita, Patel, Chintan, Schreiber, Nicole A., Curtis, Kristen Rebecca, Maslyar, Daniel J., Lemahieu, Vanessa, Fine, Bernard M., Mamounas, Michael J., Ungewickell, Alexander Joachim, Lackner, Mark R., Scher, Howard I., Kabbarah, Omar

“…Abstract only…”
Get full text

A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) by Danila, Daniel Costin, Szmulewitz, Russell Zelig, Higano, Celestia S., Gilbert, Houston, Kahn, Robert S., Wood, Katie, Agarwal, Priya, Lin, Kedan, Kabbarah, Omar, Fine, Bernard M., Maslyar, Daniel J., Vaishampayan, Ulka N.

“…Abstract only 5020 Background: Six-transmembrane epithelial antigen of the prostate-1 (STEAP1) protein is a cell-surface antigen overexpressed in human…”
Get full text

A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non− small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC) by Gordon, Michael S., Gerber, David E., Infante, Jeffrey R., Xu, Jian, Shames, David S., Choi, Younjeong, Kahn, Robert S., Lin, Kedan, Wood, Katie, Maslyar, Daniel J., Burris, Howard A.

“…Abstract only 2507 Background: NaPi2b (SLC34A2) is a multi-transmembrane, sodium-dependent phosphate transporter expressed in non-squamous NSCLC and…”
Get full text